Heart failure patients may have a readily available biomarker that helps predict their prognosis sitting in routine blood panels. This finding could transform how clinicians assess risk in the millions of Americans living with reduced heart pumping function, potentially identifying high-risk patients earlier for more aggressive interventions.
Analysis of over 8,000 heart failure patients revealed that those with lactate dehydrogenase levels in the highest quartile (253 U/L) faced significantly worse outcomes compared to the lowest quartile (155 U/L). The enzyme, present in virtually all human cells, showed a clear dose-response relationship with cardiovascular events. Patients with moderately elevated LDH (207 U/L) had 39% higher risk of heart failure hospitalization or cardiovascular death, while those with the highest levels faced even greater danger. Higher LDH correlated with multiple markers of organ stress including elevated kidney function tests, liver enzymes, and cardiac injury markers.
This represents more than academic curiosity about cellular damage markers. LDH testing costs pennies and appears on standard metabolic panels, making it immediately accessible without additional healthcare expenses. The enzyme's broad cellular distribution means elevated levels likely reflect the multi-organ impact of advanced heart failure rather than isolated cardiac damage. However, the non-specific nature of LDH elevation presents limitations—levels rise with muscle injury, hemolysis, or liver disease, potentially confounding interpretation. While this single-trial analysis shows promise, validation across diverse heart failure populations remains necessary before clinical implementation. The finding suggests inexpensive routine labs might harbor untapped prognostic information for cardiovascular specialists.